Overview
Doron Therapeutics is a clinical-stage biotechnology company developing regenerative biologic therapies for degenerative musculoskeletal conditions. The company's lead candidate, MOTYS (PTP-001), is an intra-articular biologic derived from placental tissue and classified as a Regenerative Medicine Advanced Therapy (RMAT), currently in Phase 3 clinical development for symptomatic knee osteoarthritis. MOTYS operates through a multifactorial mechanism targeting inflammation reduction, cartilage degeneration prevention, and tissue regeneration. The company is advancing its therapeutic pipeline with the goal of restoring mobility and improving quality of life for patients with joint-related degenerative conditions.